Loading data
DBDNYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.81 bn USD | 3.75 bn USD | — | 3.46 bn USD | 3.91 bn USD |
| Cost of revenue | 2.84 bn USD | 2.83 bn USD | — | 2.7 bn USD | 2.86 bn USD |
| Gross profit | 961.2 m USD | 920 m USD | — | 757.3 m USD | 1.04 bn USD |
| Research and development expense | 86.7 m USD | 93.6 m USD | — | 120.7 m USD | 126.3 m USD |
| Selling, general and administrative expense | 632.5 m USD | 643.6 m USD | — | 741.6 m USD | 775.6 m USD |
| Operating profit | 242 m USD | 182.1 m USD | — | -211.7 m USD | 137.1 m USD |
| Interest expense | — | — | — | 199.2 m USD | 195.3 m USD |
| Profit before tax | 125.1 m USD | 47.3 m USD | — | -438.6 m USD | -50.7 m USD |
| Income tax expense | 24.1 m USD | 64.3 m USD | — | 149.2 m USD | 27.7 m USD |
| Net income (reported basis) | 97.5 m USD | -14.5 m USD | 1.38 bn USD | -581.4 m USD | -78.8 m USD |
| Basic earnings per share | 2.57 USD/share | -0.44 USD/share | — | -7.36 USD/share | -1.01 USD/share |
| Diluted earnings per share | 2.54 USD/share | -0.44 USD/share | — | -7.36 USD/share | -1.01 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.